Er OON denied as non-formulary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for er oon are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies Extended-Release Opioids as Non-Formulary

UnitedHealthcare maintains a tiered formulary, and not every extended-release opioid formulation — particularly abuse-deterrent variants — is included at every tier or in every plan variant. A non-formulary denial means the specific drug or formulation is not on your plan's covered drug list for your benefit year. This is a coverage determination, and it is distinct from a safety or clinical judgment.

## Why This Denial Is Appealable

Plans are required to offer a formulary exception process. If a formulary alternative would be clinically inferior, contraindicated, or has already been tried and failed, your prescriber can document why the non-formulary drug is medically necessary for you specifically — which is the basis for a formulary exception. ACA-compliant plans must have a meaningful exception pathway.

## Federal Appeal Framework

• Formulary exception request: This is the first step — distinct from a standard appeal. Your prescriber submits a statement of medical necessity explaining why no formulary alternative is adequate.
• Internal appeal: If the exception is denied, file a formal internal appeal. Deadline appears on your denial notice.
• External review (ACA §2719): After internal exhaustion, file for independent external review within approximately four months of the final denial.
• ERISA §503: Employer-plan members are entitled to full-and-fair review with access to the criteria and evidence used.

## Appeal Process and Timeline

1. Obtain your plan's current formulary and identify formulary-tier alternatives for extended-release opioids. 2. Have your prescriber review each alternative and document — in writing — why each is clinically inadequate: prior failure, documented intolerance, or a specific clinical characteristic of the non-formulary drug that the alternatives lack (e.g., abuse-deterrent properties relevant to your clinical profile). 3. Submit a formulary exception request with that documentation attached. 4. If denied, file a formal internal appeal and, if needed, escalate to external review.

## Documentation to Gather

• Diagnosis and clinical severity: Chart notes establishing the chronic-pain condition and its functional impact.
• Formulary-alternative trial history: Dates, agents, outcomes — or a documented clinical reason why each alternative was not appropriate to trial.
• Prescriber letter: Stating why the non-formulary formulation is medically necessary and why formulary alternatives are not clinically equivalent for this patient.
• Pharmacy records: Supporting the prior-trial history where applicable.

## Criteria-Mapping Structure

Obtain the formulary exception criteria from UHC's published policy or Evidence of Coverage. List each requirement. For each, document the chart evidence or prescriber statement that satisfies it. Present this mapping directly in the appeal letter. Where the basis is the FDA prescribing label — for example, to establish the drug's approved indication — attach the relevant label section.